This site uses cookies. By using this site you agree to receiving cookies. View Policy.

Capital at risk
Regenerative Medical Group
days left
12
32%
Raised
£64,080
Investors
35
Target
£200,000
Equity
4.76%
Pre-money valuation
£4,000,000

Regenerative Medical Group provides a solution for Erectile Dysfunction (ED) and Wound (Diabetic) Healing by the use of non-invasive technology. RMG estimates that the ED market in the UK is around 5 million men and a further 5 million in the lifestyle market who are not classified as ED.

  • Operational with one brand and has achieved £400k rev
  • Aim to validate with NHS within 18 months, our estimates suggest it could produce £300m rev p.a
  • Brand established with ambassador Sir Ian Botham
  • Non-invasive, effective and no side effect medical technologies

Idea

RMG, under the Vigore brand, is a healthcare service providing regenerative shockwave treatment for erectile dysfunction. Offering a long term, no side effect, no drug solution for erectile dysfunction. The same technology will be used on chronic wounds (to improve outcomes for diabetic with Chronic foot ulcers at lower cost). We operate through a licensed technology.

We partner with clinics to provide the service, avoiding direct overhead costs. As part of the partnerships the clinics provide; reception, nurses and treatment rooms. RMG trains the nurses, acquires bookings and is responsible for the marketing. The Vigore brand has been endorsed by Sir Ian Botham as the ambassador.

In addition to the ED market we have identified wound healing as a new market (the technology is already proven). We are working with an experienced NICE/NHS validation team to demonstrate its value as a treatment modality.

Current methods for wound healing are very costly and less effective than our solution. In a £5bn/year NHS spend, our method can reduce this significantly and also reduce key KPI's such as "bed blocking"

RMG reached revenues of £400k, -56k EBITDA in FY 17, and operational in 5 clinics. RMG advises that it has treated more than 450 patients to date. We are now seeking further investment to grow rapidly.

We estimate the market size for ED is between 5 and 10 million men in the UK.

THE MATERIALS YOU ARE SEEKING TO ACCESS ARE BEING MADE AVAILABLE BY THE COMPANY RAISING FINANCE AS IDENTIFIED ABOVE (THE "COMPANY") IN GOOD FAITH AND FOR INFORMATION PURPOSES ONLY AND SUBJECT TO THESE TERMS AND CONDITIONS.  CROWDCUBE CAPITAL LTD IS AUTHORISED BY THE FCA AND CARRIES OUT DUE DILIGENCE ON EACH COMPANY THAT LISTS ON CROWDCUBE AS SET OUT HERE.
 
This investment opportunity is not an offer to the public and is only available to registered members of Crowdcube.com who have qualified and categorised themselves as able to invest.  The investment opportunity is not directed at persons located in the United States, Canada or Japan. Any person resident outside the United Kingdom who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict access.
In particular, unless otherwise determined by the Company and permitted by applicable law and regulation, it is not intended, subject to certain exceptions, that any offering of the securities mentioned in such materials (the "Securities") by the Company would be made, or any documentation be sent in or into, the United States, Canada or Japan.  There will be no public offering of the Securities in the United States.
 
In order to access the pitch you must first become a qualifying member of Crowdcube on the basis of your status as either (i) self-certified ‘high net worth investor’, (ii) certified ‘sophisticated investor’, (iii) self-certified as a ‘sophisticated investor’ or (iv) certified as a ‘restricted investor’, in each case in accordance with the FCA’s Conduct of Business Sourcebook Chapter 4.7.  Potential investors are encouraged to "cross examine" the Company by interactive due diligence and use of the available online forums to bring the "wisdom of the crowd" to bear.  Accessing the pitch also means you agree to Crowdcube’s most recent website terms and conditions and investor terms and conditions, which include Crowdcube's limitation of liability.
 
If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.  Crowdcube’s or the Issuer’s press announcements and this information page do not constitute an offer to sell securities of the Company.  Further, it does not constitute a recommendation by the Company, Crowdcube or any other party to sell or buy securities in the Company.
 
By registering or logging into Crowdcube.com to view the investment opportunity, you certify that you are legally entitled to view the investment opportunities, are an authorised investor and you agree to all applicable terms and conditions on this website, including this disclaimer.

To see the rest of the Regenerative Medical Group pitch, join now.
It’s free, quick and easy.

Join

Already registered? Log in

To see the rest of the Regenerative Medical Group pitch, join now.
It’s free, quick and easy.

Regenerative Medical Group

Join to read more information about the Regenerative Medical Group team, documents, and what other investors are saying about the pitch.

If you choose to invest we won’t take your money until the pitch closes and you can cancel your investment at any time.

Crowdcube is a leading investment crowdfunding platform

Successfully Invested
£689m+
Registered Investors
753k+